Date of Award

Spring 4-2017

Document Type


Degree Name

Master of Science (MS)



First Advisor

Daniel Widzowski, Ph.D.

Second Advisor

Robert Hinrichsen, Ph.D.

Third Advisor

Thomas Simmons, Ph.D.

Fourth Advisor

Idamarie Laquatra, Ph.D.


Both high fat diets and antihistamines have been implicated in human and animal metabolic disorders. Interaction of these factors is poorly understood. Omega-3 hepatoprotection is under-studied regarding drug-diet interactions. Two murine studies examined high fat versus omega-3 fatty acid diets and fexofenadine administration on metabolic disturbances. Based on run-in period, fexofenadine altered body weights specific to dietary grouping. With longer run-in times, fexofenadine and high-fat diet increased fat pad, liver, and body weights, while omega-3 body weights matched control. In contrast, shorter run-in times resulted in body weight decreases in high fat and omega-3-fed fexofenadine-treated mice, as well as increased fat pad masses and reduced serum glucose concentrations. Fexofenadine administration appears to affect body weight dependent on dietary fat and pre-drug run-in periods. Stress-induced biological factors may play a role in acclimation of mice to study conditions.